{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:35:03Z","timestamp":1791153303390,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.vaccine.2008.10.088","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T13:22:53Z","timestamp":1227705773000},"page":"581-587","source":"Crossref","is-referenced-by-count":124,"title":["Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15\u201355 years"],"prefix":"10.1016","volume":"27","author":[{"given":"Tino F.","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Spaczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Wysocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Galaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Perona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylviane","family":"Poncelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toufik","family":"Zahaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Dubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1 (September)","key":"10.1016\/j.vaccine.2008.10.088_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"9 (May 3)","key":"10.1016\/j.vaccine.2008.10.088_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/jnci\/92.9.690","article-title":"Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis","volume":"92","author":"zur Hausen","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"1 (June 20)","key":"10.1016\/j.vaccine.2008.10.088_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"issue":"5 (March 1)","key":"10.1016\/j.vaccine.2008.10.088_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/427557","article-title":"Development and duration of human papillomavirus lesions, after initial infection","volume":"191","author":"Winer","year":"2005","journal-title":"J Infect Dis"},{"issue":"4 (April)","key":"10.1016\/j.vaccine.2008.10.088_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"issue":"6 (February 6)","key":"10.1016\/j.vaccine.2008.10.088_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"issue":"Suppl 1 (March 30)","key":"10.1016\/j.vaccine.2008.10.088_bib7","first-page":"S1","article-title":"The epidemiology of genital human papillomavirus infection","volume":"24","author":"Trottier","year":"2006","journal-title":"Vaccine"},{"issue":"11 (June 1)","key":"10.1016\/j.vaccine.2008.10.088_bib8","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1086\/428779","article-title":"A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica","volume":"191","author":"Castle","year":"2005","journal-title":"J Infect Dis"},{"issue":"7 (July)","key":"10.1016\/j.vaccine.2008.10.088_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"1 (July 7)","key":"10.1016\/j.vaccine.2008.10.088_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bjc.6601024","article-title":"Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis","volume":"89","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"issue":"5A (May 5)","key":"10.1016\/j.vaccine.2008.10.088_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am J Med"},{"issue":"1 (February)","key":"10.1016\/j.vaccine.2008.10.088_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2303.2001.00288.x","article-title":"Adenocarcinoma of the uterine cervix compared with squamous cell carcinoma: a 12-year study in Southampton and South-west Hampshire","volume":"12","author":"Herbert","year":"2001","journal-title":"Cytopathology"},{"issue":"9447 (November 13)","key":"10.1016\/j.vaccine.2008.10.088_bib13","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9518 (April 15)","key":"10.1016\/j.vaccine.2008.10.088_bib14","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4,5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.vaccine.2008.10.088_bib15","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"issue":"Suppl 3 (August 21)","key":"10.1016\/j.vaccine.2008.10.088_bib16","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.vaccine.2006.05.110","article-title":"Chapter 12: prophylactic HPV vaccines: underlying mechanisms","volume":"24","author":"Stanley","year":"2006","journal-title":"Vaccine"},{"issue":"4 (April)","key":"10.1016\/j.vaccine.2008.10.088_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrmicro867","article-title":"Delivering on the promise: HPV vaccines and cervical cancer","volume":"2","author":"Schiller","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"15 (August 6)","key":"10.1016\/j.vaccine.2008.10.088_bib18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"9580 (June 30)","key":"10.1016\/j.vaccine.2008.10.088_bib19","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"issue":"2 (March)","key":"10.1016\/j.vaccine.2008.10.088_bib20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1128\/CDLI.11.2.399-405.2004","article-title":"Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions","volume":"11","author":"Castle","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"6 (June)","key":"10.1016\/j.vaccine.2008.10.088_bib21","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16,18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"issue":"1 (January)","key":"10.1016\/j.vaccine.2008.10.088_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","article-title":"Natural history of human papillomavirus type 16 virus-like particle antibodies in young women","volume":"13","author":"Ho","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Mar (2)","key":"10.1016\/j.vaccine.2008.10.088_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/CDLI.4.2.122-126.1997","article-title":"Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women","volume":"4","author":"Viscidi","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"issue":"11 (December 1)","key":"10.1016\/j.vaccine.2008.10.088_bib24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1086\/344271","article-title":"The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis","volume":"35","author":"Fisman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2008.10.088_bib25","unstructured":"Wheeler CM, Teixeira J, Romanowski B, De Carvalho N, Dubin G, Schuind A. High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix\u2122 (GSK HPV-16\/18 AS04 vaccine). May 14\u201316, Graz, Austria; 2008."},{"issue":"1","key":"10.1016\/j.vaccine.2008.10.088_bib26","first-page":"158","article-title":"Sustained immunogenicity and high efficacy against HPV-16\/18 related cervical neoplasia: long-term follow up through 6, 4 years in women vaccinated with Cervarix\u2122 (GSK's HPV 16\/18 AS04 candidate vaccine)","volume":"109","author":"Harper","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"33\u201334 (June 19)","key":"10.1016\/j.vaccine.2008.10.088_bib27","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"issue":"9 (May 1)","key":"10.1016\/j.vaccine.2008.10.088_bib28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1086\/429240","article-title":"Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine","volume":"40","author":"Bernstein","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3 (December 2)","key":"10.1016\/j.vaccine.2008.10.088_bib29","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.vaccine.2004.06.006","article-title":"Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04","volume":"23","author":"Boland","year":"2004","journal-title":"Vaccine"},{"issue":"5 (October)","key":"10.1016\/j.vaccine.2008.10.088_bib30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Garcon","year":"2007","journal-title":"Expert Rev Vaccines"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08015004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X08015004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:51:09Z","timestamp":1589190669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X08015004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0264410X08015004"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2008.10.088","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}